芪茵颗粒通过调控SIRT1/LXRα信号通路影响代谢相关脂肪性肝病小鼠肝组织脂质代谢研究*

doi:10.3969/j.issn.1672-5069.2026.05.005

摘要/Abstract

摘要： 目的探讨芪茵颗粒改善高脂饮食诱导的代谢相关脂肪性肝病(MAFLD)小鼠肝脏脂质代谢影响的可能机制。方法取C57BL/6J小鼠,随机分为对照组、模型组、吡格列酮二甲双胍处理组和小、中、大剂量芪茵颗粒处理组,每组10只。给予高脂饮食制备模型,自第7周起给予药物灌胃6周。常规行组织病理学检查,分别采用Western blot和qRT-PCR检测肝组织SIRT1/LXRα信号通路关键分子表达水平。结果模型组血清TG和TC及肝组织TG和TC水平均显著高于对照组(P<0.05),而中、大剂量芪茵颗粒处理组上述指标均显著低于模型组(P<0.05);与模型组比,吡格列酮二甲双胍处理组及小、中、大剂量芪茵颗粒处理组肝组织SIRT1蛋白表达上调(P<0.05),而LXRα、SREBP-1c和FASN蛋白表达显著下调,呈剂量依赖性(P<0.05);与模型组比,吡格列酮二甲双胍处理组及小、中和大剂量芪茵颗粒处理组SIRT1 mRNA水平上调(P<0.05),而LXRα、SREBP-1c和FASN mRNA水平显著下调(P<0.05),呈剂量依赖性变化。结论芪茵颗粒可能通过调控SIRT1/LXRα 信号通路,抑制脂质新生并减轻炎症反应,从而有效改善MAFLD小鼠肝脂肪变性。

Abstract: Objective This experiment aimed to investigate mechanism by which Qiyin granules (QY), a herbal medicine, improve hepatic lipid metabolism in high-fat diet (HFD)–induced metabolic-associated fatty liver disease (MAFLD). Methods 60 C57BL/6J mice were randomly divided into control, model, pioglitazone /metformin-intervened, low, medium and high-dose Qiyin granules-intervened group, with 10 in each. Model was establish by HFD feeding, and interventions began at seven weeks for six weeks. Liver histopathological study was routinely conducted, and hepatic SIRT1/LXRα signaling pathway genes and their proteins were detected by Western blotting and qRT-PCR, respectively. Results Serum and hepatic triglycerides and total cholesterol levels in model group increased greatly as compared to in the control(P<0.05), while they decreased obviously in pioglitazone /metformin-intervened, and low, medium and high-dose Qiyin granules-intervened group(P<0.05);hepatic SIRT1 protein in pioglitazone /metformin-intervened, and low, medium and high-dose Qiyin granules-intervened group upregulated(P<0.05),while hepatic LXRα, SREBP-1c and FASN protein expression down-regulated greatly as compared to in the model (P<0.05); hepatic SIRT1 mRNA levels in pioglitazone /metformin-intervened, and low, medium and high-dose Qiyin granules-intervened group increased in a dose-dependent manner(P<0.05),while hepatic LXRα, SREBP-1c and FASN mRNA levels decreased obviously (P<0.05), as compared to in the model. Conclusions Qiyin granules could ameliorate HFD-induced MAFLD, maybe via modulating the SIRT1/LXRα signaling pathway, which might suppress de novo lipogenesis and attenuate inflammation.

Key words: Metabolic-associated fatty liver disease, Qiyin granules, a herbal medicine, SIRT1, LXRα, Mice

姚秋月, 雷云霞. 芪茵颗粒通过调控SIRT1/LXRα信号通路影响代谢相关脂肪性肝病小鼠肝组织脂质代谢研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 657-660.

Yao Qiuyue, Lei Yunxia. Effects of Qiyin granules on hepatic lipid metabolism in mice with metabolic-associated fatty liver disease by regulating the SIRT1/LXRα signaling pathway[J]. Journal of Practical Hepatology, 2026, 29(5): 657-660.

参考文献

[1] Targher G, Valenti L, Byrne CD. Metabolic dysfunction-associated steatotic liver disease. N Engl J Med,2025, 393(7):683-698.
[2] Tauil RB, Golono PT, De Lima EP, et al. Metabolic-associated fatty liver disease: The influence of oxidative stress, inflammation, mitochondrial dysfunctions, and the role of polyphenols. Pharmaceuticals (Basel), 2024, 17(10):1221-1228.
[3] Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology, 2023,77(4):1335-1347.
[4] 唐晓路,邓玲,王金春,等.水飞蓟素联合甘草酸二铵治疗非酒精性脂肪性肝炎患者疗效临床研究.实用肝脏病杂志,2025,28(4):537-540.
[5] Dai X, Feng J, Chen Y, et al. Traditional Chinese medicine in nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Chin Med, 2021,16(1):68.
[6] 刘阳军, 郭峰, 曾斌芳. 芪茵颗粒治疗非酒精性脂肪性肝病(肝郁脾虚型)临床研究.新疆中医药, 2008, (3): 8-10.
[7] Meng D, Zhang F, Yu W, et al. Biological role and related natural products of SIRT1 in nonalcoholic fatty liver. Diabetes Metab Syndr Obes, 2023, 16:4043-4064.
[8] Kim H, Park C, Kim TH. Targeting liver X receptors for the treatment of non-alcoholic fatty liver disease. Cells, 2023, 12(9):1292.
[9] Chang N, Li J, Lin S, et al. Emerging roles of SIRT1 activator, SRT2104, in disease treatment. Sci Rep, 2024,14(1):5521.
[10] Han J, Li S, Wang W, et al. SIRT1 activator E1231 alleviates nonalcoholic fatty liver disease by regulating lipid metabolism. Curr Issues Mol Biol, 2023,45(6):5052-5070.
[11] Guo J, Chen S, Zhang Y, et al. Cholesterol metabolism: physiological regulation and diseases. Med Comm,2024,5(2):e476.
[12] Lockhart SM, Muso M, Zvetkova I, et al. Damaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health. Nature metabolism, 2024, 6(10): 1922-1938.
[13] Shen S, Shen M, Kuang L, et al. SIRT1/SREBPs-mediated regulation of lipid metabolism. Pharmacol Res, 2024, 199: 107037.
[14] Yan X, Liu H, Huang M, et al. Integrative proteomics and metabolomics explore the effect and mechanism of Qiyin granules on improving nonalcoholic fatty liver disease. Heliyon, 2024, 10(5): e27075.
[15] Ponugoti B, Kim DH, Xiao Z, et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. Biol Chem, 2010, 285(44): 33959-33970.
[16] Shen S, Shen M, Kuang L. SIRT1/SREBPs-mediated regulation of lipid metabolism. Pharmacol Res, 2024, 199: 107037.
[17] Tian C, Huang R, Xiang M. SIRT1: Harnessing multiple pathways to hinder NAFLD. Pharmacol Res, 2024, 203: 107155.
[18] Liao J, Xie X, Wang N, et al. Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway. Phytomedicine, 2024, 124: 155285.
[19] He S, Wang Y, Liu J, et al. Activating SIRT1 deacetylates NF-κB p65 to alleviate liver inflammation and fibrosis via inhibiting NLRP3 pathway in macrophages. Int J Med Sci, 2023, 20(4): 505-519.
[20] Li X, Zhang S, Liu X, et al. Metabolic mechanisms orchestrated by sirtuin family to regulate immunity and inflammation: Focus on SIRT1–NF-κB axis. Front Immunol, 2024, 14: 1448535.

芪茵颗粒通过调控SIRT1/LXRα信号通路影响代谢相关脂肪性肝病小鼠肝组织脂质代谢研究^*

Effects of Qiyin granules on hepatic lipid metabolism in mice with metabolic-associated fatty liver disease by regulating the SIRT1/LXRα signaling pathway

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	罗轲, 张丹眉, 郭金, 龚作炯. LPS/D-gal诱导急性肝衰竭小鼠肝组织cGAS-STING通路蛋白表达及其肝素保护作用研究[J]. 实用肝脏病杂志, 2026, 29(5): 649-652.
[2]	吴小雪, 王昕钰, 胡鸿阳, 李秀惠, 张向颖. 清肠利肝方对ANIT诱导的胆汁淤积性肝损伤小鼠保护作用机制研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 653-656.
[3]	林静, 贾纪会, 段钟平, 陈煜, 张晓慧. D-GalN/LPS诱导的急性肝衰竭小鼠肝组织cGAS-STING通路基因水平变化^*[J]. 实用肝脏病杂志, 2026, 29(4): 485-488.
[4]	刘江, 袁涵, 凌芬, 李东海. 脯氨酸加格列净通过抑制DPP4/NOX1介导的氧化应激反应改善代谢相关脂肪性肝病小鼠肝脂肪变性^*[J]. 实用肝脏病杂志, 2026, 29(4): 489-492.
[5]	罗轲, 王钰鲲, 郭金, 石春霞, 龚作炯. 甜菜碱通过调节JNK/STAT3信号通路缓解LPS/D-gal诱导的急性肝衰竭小鼠肝损伤实验研究^*[J]. 实用肝脏病杂志, 2026, 29(1): 13-16.
[6]	杨思琪, 陈佳炜, 李少涵, 郭雪, 黄琛, 陈慧婷, 周永健. Coprococcus eutactus改善代谢相关性脂肪性肝病小鼠肝组织脂肪代谢实验研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 813-817.
[7]	王庆菁, 范建高, 沈峰, 张骞仁, 任天羿, 汪余勤. NAT10促进肝大部切除术小鼠肝再生实验研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 651-654.
[8]	杨欢, 袁宏伟, 奇丽娜, 陈平. 代谢相关脂肪性肝病患者肝组织学表现研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 711-714.
[9]	齐一菲, 于庆红, 白世锦, 刘琳, 范旭, 王萍, 丛敏, 刘天会. 二乙基二硫代氨基甲酸通过Insr/Akt通路改善代谢相关脂肪性肝炎体内和体外实验研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 501-504.
[10]	韩煜东, 张杰, 章文瑾, 何年安. 超声来源的脂肪分数诊断代谢相关脂肪性肝病应用研究[J]. 实用肝脏病杂志, 2025, 28(4): 553-556.
[11]	杨浩, 易波, 刘洪岩. T2DM合并代谢相关脂肪性肝病患者血清IFN-α和IFN-β水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(4): 557-560.
[12]	刘倩, 杨洁, 张静, 宫克, 郭瑞丹. 慢性乙型肝炎合并代谢相关脂肪性肝病患者外周血单个核细胞Galectin-3和Galectin-9水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(3): 338-341.
[13]	卫涛涛, 刘天烨, 戴高中. 代谢相关脂肪性肝病患者回肠菌群特征研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 354-357.
[14]	董旭, 王超群, 陈怡, 朱彤, 葛玲玲, 徐爱静. 估算葡萄糖处置率评估无糖尿病人群代谢相关脂肪性肝病发生风险效能研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 362-365.
[15]	秦浩, 方春华, 何競, 张磊, 冉斌, 汪丽萍, 张振华. 六种无创评分诊断2型糖尿病合并代谢相关脂肪性肝病患者效能比较^*[J]. 实用肝脏病杂志, 2025, 28(3): 366-369.